Infanrix IPV
Details for Infanrix IPV vaccine and its components.
Sponsor:
GlaxoSmithKline Australia
Administration route:
Intramuscular injection
Vaccine group:
Combination vaccines
Registered for primary immunisation in infants aged ≥6 weeks and as a booster in children aged ≤6 years.
DTPa-IPV — diphtheria-tetanus-acellular pertussis-inactivated poliovirus combination vaccine
Each 0.5 mL monodose pre-filled syringe contains:
- ≥30 IU diphtheria toxoid
- ≥40 IU tetanus toxoid
- 25 µg pertussis toxoid
- 25 µg filamentous haemagglutinin
- 8 µg pertactin
- 40 D-antigen units inactivated poliovirus type 1 (Mahoney)
- 8 D-antigen units inactivated poliovirus type 2 (MEF-1)
- 32 D-antigen units inactivated poliovirus type 3 (Saukett)
Adsorbed onto aluminium hydroxide.
Also contains traces of:
- formaldehyde
- polysorbate 80
- polymyxin
- neomycin
For full details, refer to the product information and consumer medicine information sheets for Infanrix IPV vaccine available on the TGA website.
Page history
Last updated:
4 June 2018
Last reviewed:
4 June 2018
Definitions
- DTPa
- diphtheria-tetanus-acellular pertussis vaccine
- IPV
- inactivated poliomyelitis vaccine
- IU
- international units
Printed content may be out of date. For up to date information, always refer to the digital version: https://immunisationhandbook.health.gov.au/vaccines/infanrix-ipv.